EMERYVILLE, Calif. (July 13, 2020) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces testing results from an independent third-party laboratory confirming that Avenova®, NovaBay’s proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2. Test results will be submitted to the Environmental Protection Agency (EPA) for the EPA’s approved list of disinfectants for use against SARS-CoV-2.
“Since Avenova’s inception, we have known it to be a powerful antimicrobial spray solution, effective against all types of pathogens, including a wide variety of viruses, bacteria, and fungi. Now we have results from a highly reputable independent laboratory confirming Avenova kills the coronavirus that causes COVID-19,” said Justin Hall, NovaBay CEO.
The study was designed to determine Avenova’s effectiveness against the SARS-CoV-2 on a hard surface. Testing was performed with the USA-WA1/2020 strain of SARS-CoV-2 at room temperature (20 degrees Celsius [68 degrees Fahrenheit] +/- 1 degree) in a 5.0% serum in viral inoculum on a glass Petri dish. Avenova (active ingredient of 0.01% hypochlorous acid in saline solution) was sprayed on the surface from a distance of six to eight inches until the surface was thoroughly wet. Results at 60 seconds prove Avenova’s ability to fully inactivate the virus.
“Most COVID-19 transmission is likely due to person-to-person contact as respiratory droplets containing the virus spread through the air by speaking or even breathing, and reach others in close proximity. These large droplets transmit the virus by entering the body typically through the eyes, nose or mouth,” explained Mr. Hall.
“Avenova, formulated with our pure, FDA-cleared hypochlorous acid, is completely non-toxic and is safe for use on all skin surfaces, including delicate facial skin around eyes, nose and mouth. As a cautionary note, I would like to warn consumers that not all hypochlorous acid products are alike. Some are not designed for use on skin the way Avenova is, and others are not as pure and should not be used on skin on a daily basis. Additionally, some hypochlorous acid products are not of a high pharmaceutical grade like ours and may not maintain a sufficiently high concentration of hypochlorous acid to kill SARS-CoV-2.”
As previously announced, NovaBay continues to work with the U.S. Food and Drug Administration (FDA) on the Emergency Use Authorization (EUA) for the fluorecare® SARS-CoV-2 IgG & IgM Antibody Combined (colloidal gold chromatographic immunoassay) Test Kit. The FDA has not provided a timeline for completion of the review.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, CELLERX® for the aesthetic dermatology market and NEUTROPHASE® for the wound care market. Avenova is the only lab-tested, truly pure Hypochlorous Acid that is patented and FDA cleared. Avenova is made in the USA.
Forward-Looking Statements and Disclaimers
This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our ability to obtain approval for Avenova to be listed on the EPA’s list of disinfectants, the use of Avenova as relates to COVID-19 and the impact such approval and usage may have on our future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to further consumer acceptance of Avenova, and any potential damage to our established goodwill in the marketplace. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
No statements contained in this press release are meant to infer that Avenova is a treatment for COVID-19 or that the use of Avenova would prevent the contraction of the disease. There is no known treatment, nor is there an FDA approved treatment for COVID-19. The study completed was in-vitro only and did not involve live subjects. The data reflects Avenova’s effectiveness against the virus on a hard surface, not skin.
President and Chief Executive Officer
LHA Investor Relations